Abstract:Purpose: To investigate the radiolabeling of E-B5, a monoclonal antibody against Pro-GastrinReleasing Peptide(31-98)by Iodine and study the stability and immunoreactivity of I-E-B5. To determine the in vivo biodistribution of I-E-B5 in normal Kunming mouse and small cell lung cancerbearing nude mouse models(SCLC mouse model) to study the pharmacokinetics of the I-E-B5 in vivo. Characterize the radioimmunoimaging effect and the best imaging time of I-E-B5 in different types of tumors. Methods: I-E-B5 was labeled by chloramine–T method. The labeling efficiency and radiochemical purity were determined by thin-layer chromatography. The I-E-B5 was incubated at 37°C water bath by itself or mixed with normal human serum, the radiochemical purity was then checked at different time points to determine its stability, and the immunoreactivity was determined by cell binding assays.I-E-B5 was injected into the tail veins of the normal Kunming mice which were sacrificed at different time points after injection, and the blood and representative tissues were collected immediately, and the %ID/g (percentage injected dose per gram of tissue) and pharmacokinetic parameters were calculated at various time points. Similarly, T/NT (tumor to non-tumor radioacticity ratio) at various time points were calculated after injection of I-E-B5 into the SCLC model. Mouse models bearing small cell lung cancer, lung adenocarcinoma, colon cancer were utilized to study the radioimmunoimaging effect of I-E-B5, and calculate the T/B ratio (tumor volume to the corresponding location at the other side). Results: I-E-B5 labeling rate was 90.8%, radiochemical purity was 99.28%, and radioactivity was 2.69 MBq/ug. The radiochemical purity of I-E-B5 was 90% after 6 hr at 37°C water bath, and remained at more than 70% after 24 hrs. The radiochemical purity was over 68.1% after 24 hrs mixing with normal human serum. The immunobinding rate of I-E-B5 to NCI-H446 (SCLC cell lines) and A549 (lung adenocarcinoma cell lines) was 71.6%, and 33.2%, respectively. The pharmacokinetics of I-E-B5 is consistent with a two-compartment model with first-order absorption. It was primarily metabolized via liver and kidney. The serum clearance rate is relatively fast. The %ID/g of I-E-B5 in xenografts was dramatically increased to a level much higher than other tissues 48 hrs after injection, reached plateau at 72 hr, and the T/NT ratio was also gradually increased with time. Prominent uptake of I-E-B5 in xenografts of SCLC in nude mice was observed after 24 hrs of injection. The radioactivity in the xenografts was gradually increased with time, and reached the peak at 72 and 96 hr. Xenografts of colon cancer showed similar results as that of SCLC although at a lower level. No observable accumulation was seen in the xenografts of lung adenocarcinoma. The T/B ratio in xenografts of SCLC was consistently higher than in colon cancer at all the time points, and both were significantly higher than that of lung adenocarcinoma which remained stable during the observation duration. Conclusion: The labeling rate and radiochemical purity of I-E-B5 were high and stable both in vivo and vitro. The labeled E-B5 kept its immunologic activity. I-E-B5 selectively accumulated at tumors expressing proGRP, and could effectively target SCLC, therefore is a promising radioimmunoimaging reagent for SCLC.

In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model.

Tumor Targeting of 125I-Labeled Anti-Egfr Monoclonal Antibody LA22 in HT-29 Human Colon Cancer

Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C.

Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues

Characterization of 177Lu-Affibody-hsa Bioconjugate for Radionuclide Therapy of Egfr-Expressing Head and Neck Carcinomas

Accurate Determination of Internalization for Target Binding Antibody Using Papain Digestion and Flow Cytometry

Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody

PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.

A Novel Method Measuring Internalization in Tumor Cells by Cell Pretargeting

Evaluation of the internal therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in nude mice with colorectal cancer

INTERNALIZATION OF RADIOLABELED MG SERIES MONOCLONAL ANTIBODIES AGAINST HUMAN GASTRIC CANCER

177Lu–do3a–hsa–zegfr:1907: Characterization As a Potential Radiopharmaceutical for Radionuclide Therapy of EGFR-expressing Head and Neck Carcinomas

Inhibitory Effect of 131 I-labeled Epidermal Growth Factor Receptor-Targeted Liposome Nanoparticle on EGFR-overexpressing Cancer Cells in Vitro

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64cu Labeled Affibody Protein

Preparation of Egfr Monoclonal Antibody Conjugated Nanoparticles and Targeting to Hepatocellular Carcinoma

Experimental study of pharmacokinetics and radioimmunoimaging of 131 Iodine-labeled monoclonal antibody E-B 5 against Pro-Gastrin-Releasing Peptide ( 31-98 )

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Evaluation of Four Affibody Based Near-Infrared Fluorescent Probes for Optical Imaging of Epidermal Growth Factor Receptor Positive Tumors

Studies on the distribution and radioimmunoimaging of 99m Tc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts

Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy

Camouflaging Irgd-Egfr Anchored Human Cytotoxic T-lymphocyte Membranes to the Surface of Nanoparticles Combined with Low-Dose Irradiation: New Approach to Enhance Drug-Delivery Targeting in Gastric Cancer